Biotech Stock Mailbag: Year in Review

BOSTON (TheStreet) -- After re-reading all of the Biotech Stock Mailbag columns published in 2009, it's quite clear I wrote often about Cell Therapeutics (CTIC) and Hemispherx Biopharma (HEB). Yet I also managed to find the space to write about 88 other drug and biotech stocks -- well above the 65 companies mentioned in my 2008 Mailbag columns.

Before I get to the review of my Mailbag hits and misses from 2009, I wanted to throw out an idea for a new feature I'm thinking about for next year. I'll call it the Biotech Stock Mailbag Readers' Portfolio, or BSMRP.

Basically, the idea is to create and track a biotech stock portfolio with picks that come exclusively from readers of the Biotech Stock Mailbag. Please email me three favorite biotech stocks -- long or short -- with a very short summary of why you like (or dislike) them.

I'll collect the nominees and those stocks mentioned the most by readers -- let's say the top 12-15 stocks -- will form the basis for the BSMRP.

Every month or so, perhaps more frequently, I'll devote a portion of the Mailbag to discuss the winners and losers in the portfolio. At various times of the year, perhaps I'll solicit readers' advice on stocks to sell or new ones to add.

I haven't thought through all the logistics yet, but I'd like the BSMRP to be an experiment to determine if the collective wisdom of the Mailbag community can put together a winning biotech stock portfolio.

Like I said, I'm still working out the details. In the meantime, send your three best biotech stock picks to [e-mail]. Please put BSMRP in the subject line of your email. And look for more details about the BSMRP in January.

1 2 3 Next › Last »